

Syngene

Putting Science to Work

SynVantage

**AI-enhanced relay-based drug discovery
for optimizing Design-Make-Test-Analyze
(DMTA) cycle**





SynVantage is Syngene's platform that enables a continuous and seamless transition between different stages of the Design-Make-Test-Analyze (DMTA) cycle in drug discovery.

The process ensures a relay-based changeover between scientists and other support functions who may be working in shifts in the laboratories at any stage in the drug discovery cycle.

Relay-based approach

In a relay-based model, the ownership for a discovery program lies collectively with a team of scientists. They work collaboratively in a round-the-clock shift system with a just-in-time approach, thereby eliminating inefficiencies and waste. For example, in a small molecule discovery program based on the relay-based model, a team of chemists would work in a coordinated, tandem manner on each chemical reaction step within a synthetic scheme – reagent procurement to reaction set-up, monitoring, and workup, purification, and characterization.



24/7 or 24/5 Relay-based Discovery is forecasted to truncate hit-to-lead/lead optimization timelines

The 24/7 or 24/5 relay model can be configured to cover all three work shifts on a working day with efficient planning and operations. Further, a team leader assigned to this model would ensure seamless handover between two scientists in two different shifts.



Accelerating drug discovery cycle with SynVantage

We believe that our 24/7 or 24/5 relay-based discovery can significantly reduce early discovery timelines by 12 to 18 months, depending on the type of project being handled.

Supporting SynVantage in this task are AI-based predictive algorithms that rapidly and accurately understand the patterns and molecular changes required to predict the optimal compound. This in turn, would result in:



Optimal utilization of resources



Faster response to emerging needs for therapeutic discovery



Faster time-to-market in bringing new therapies to patients in need

SynVantage can be used across Syngene's drug discovery offerings of Chemistry, Biology, Safety Assessment, and Research Informatics. All the support functions at Syngene like procurement and stores, purification, analysis, EHS, administration, IT, HR, and operations have also been enabled to complement the relay model.



Syngene
Putting Science to Work

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 4700 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK and Merck KGaA.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com

© 2022 Syngene International Limited, All Rights Reserved.

Stay Connected

